ClinicalTrials.gg
TerminatedNCT00378573Updated Jan 26, 2010Results posted

Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 2 interventional study of docetaxel and gemcitabine in Non-small Cell Lung Cancer, sponsored by Sanofi. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-01-26.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Incidence of GI Perforation

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
153rd of 188
17 · median 50
Started
2007
with 14 others
Phase 2
125 of 198
9 open now
Registered
76th of 198
by date
Lead sponsor
7 of 198
Sanofi

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 153rd largest by enrollment of the 188 interventional ones that give a count, is one of 15 that started in 2007, is one of 125 in phase 2, and was the 76th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase II prospective, multicenter study evaluating Progression Free Survival (PFS) after first line treatment with the combination of gemcitabine, docetaxel, and bevacizumab in subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). PFS will be measured from the date of registration (ie, assignment of subject number when subject meets all entry criteria) to the earliest date of documented evidence of progressive disease, or the date of death due to any cause, whichever occurs first.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Inclusion criteria

Inclusion Criteria:

  1. Histologic or cytologic confirmation of locally advanced (pleural effusion) or (Stage IIIB/IV) NSCLC (non-squamous-cell histology only), mixed tumor types can be selected based on predominant cell type unless small cell elements are discovered (in which case the subject is not eligible);
  2. , defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >/= 20 mm with conventional computerized tomography (CT) or magnetic resonance imaging (MRI) scans, or as >/= 10 mm with spiral computerized tomography (CT) scan
  3. No previous systemic chemotherapy
  4. Estimated of >/= 12 weeks
  5. (ECOG) Performance Status (PS) of 0, 1 or 2
  6. Nonpregnant, nonlactating female subjects; male and female subjects of must be willing to use an effective form of while on therapy and for 90 days thereafter; an effective form of contraception is defined as an oral contraceptive or a double barrier method; pregnancy is to be determined/ ruled out through the use of serum human chorionic gonadotropin (HCG)
  7. Subjects must have adequate renal function as determined by the following within 1 week prior to study registration: Calculated >45 mL/min using Cockcroft-Gault formula; Urine protein: creatinine (UPC) ratio \<1.0 by spot urinalysis; Urine dipstick for protein \<2+ (subjects discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \</= 1 g of protein in 24 hours to be eligible);
  8. Hematologic evaluation within 2 weeks prior to study registration (minimum values): (ANC) >/= 1500 mm3; count >/= 100,000 mm3; (Hg) >/= 9.9 g/dL (erythropoietin may be transfused to maintain or exceed this level); (PTT) no greater than (ULN)
  9. Hepatic function evaluation within 2 weeks prior to study registration (as detailed in protocol provided to Investigator): Total \</= upper limit of normal; (AST), alanine aminotransferase (ALT) and alkaline phosphatase must be within the range allowing for eligibility; In determining eligibility the more abnormal of the two values (AST or ALT) should be used (details for decision in full protocol as provided to Investigator)

Exclusion criteria

Exclusion Criteria:

  1. Receipt of prior systemic chemotherapy, vascular endothelial growth factor (VEGF) or endothelial growth factor receptor (EGFR) inhibitor therapy at any time; receipt of recent or current radiation therapy; current, recent (within 4 weeks prior to study registration), or planned receipt of therapy (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
  2. Subjects with cardiovascular diseases and related treatments
  3. Surgical procedure in anamnesis (medical history): Major surgical procedure, open , or significant traumatic injury within 28 days prior to registration, or anticipation of need for major surgical procedure during the course of the study; Minor surgical procedures (eg, fine needle aspirations, core biopsies) within 7 days prior to registration;
  4. Serious non-healing wound, ulcer, or bone fracture;
  5. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study registration;
  6. History of gross hemoptysis (defined as bright red blood of >/= 0.5 teaspoon)
  7. History of reaction to drugs formulated with polysorbate 80;
  8. Subjects with ;
  9. Peripheral neuropathy >/= Grade 2 (based on Common Toxicity Criteria Adverse Event [] v3.0);
  10. History of a other than NSCLC; exceptions to this include: Curatively treated basal cell carcinoma; cervical intraepithelial neoplasia; or localized prostate cancer with a current prostate-specific antigen (PSA) of \<1.0 ng/dL on 2 successive evaluations at least 3 months apart, and the most recent evaluation within 4 weeks of study registration; History of another malignancy that was curatively treated and no evidence of disease for a minimum of 5 years;
  11. Symptoms of a illness in the 90 days before the study, or history of other disease, (such as (HIV) positive, chronic infection (eg, pulmonary tuberculosis), or hepatitis A, B or C (active or previously treated), active infection with fever, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that might affect the interpretation of the results of the study, or render the subject at high risk from treatment complications; (testing for these conditions will be at investigator discretion)
  12. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    docetaxel, gemcitabine and bevacizumab

    Single arm treatment with docetaxel, gemcitabine and bevacizumab

    Drug: docetaxel · Drug: gemcitabine · Drug: bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival for Subjects With Locally Advanced or Metastatic (Stage IIIB or Stage IV) Non-Small Cell Lung Cancer (NSCLC) After Systemic Treatment With Gemcitabine, Docetaxel, and Bevacizumab as First Line Therapy

    Time frame: 1 year post-registration

Secondary outcomes

  1. Objective Response Rate (Complete Response [CR] Plus Partial Response [PR]) Using Response Evaluation Criteria in Solid Tumors (RECIST)

    Complete response is defined as disappearance of all target and nontarget lesions identified and reported at baseline (at or within 4 weeks before the beginning of treatment) by image-based evaluations such as computerized tomography (CT) or magnetic resonance imaging (MRI). Partial response is defined as persistence of one or more nontarget lesions and at least 30 percent decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameters.

    Time frame: 1 year from start of treatment

  2. Overall Survival

    Survival is defined as the time from the date of registration to the study to the date of death.

    Time frame: 2 years post-registration

07

Results

Posted Jan 18, 2010
Limitations and caveats
Due to early termination of the study only 17/90 subjects enrolled. Efficacy analysis of Progression Free Survival and Overall Survival were not performed. Efficacy results limited to a descriptive summary of best overall response for each subject.

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneDocetaxel, Gemcitabine and Bevacizumab
Started17
Completed0
Not completed17
Withdrew: Adverse event9
Withdrew: Physician decision1
Withdrew: Withdrawal by subject2
Withdrew: Disease progression4
Withdrew: Sponsor decision to close study1
Follow-up
Participant flow — Follow-up
MilestoneDocetaxel, Gemcitabine and Bevacizumab
Started17
Completed3
Not completed14
Withdrew: Death12
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryProgression Free Survival for Subjects With Locally Advanced or Metastatic (Stage IIIB or Stage IV) Non-Small Cell Lung Cancer (NSCLC) After Systemic Treatment With Gemcitabine, Docetaxel, and Bevacizumab as First Line Therapy
Time frame:
1 year post-registration
Reported as:
Median · Days

No measurements were reported for this outcome.

SecondaryObjective Response Rate (Complete Response [CR] Plus Partial Response [PR]) Using Response Evaluation Criteria in Solid Tumors (RECIST)

Complete response is defined as disappearance of all target and nontarget lesions identified and reported at baseline (at or within 4 weeks before the beginning of treatment) by image-based evaluations such as computerized tomography (CT) or magnetic resonance imaging (MRI). Partial response is defined as persistence of one or more nontarget lesions and at least 30 percent decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameters.

Time frame:
1 year from start of treatment
Reported as:
Number · Participants
Objective Response Rate (Complete Response [CR] Plus Partial Response [PR]) Using Response Evaluation Criteria in Solid Tumors (RECIST)
ParticipantsDocetaxel, Gemcitabine and Bevacizumab
Complete Response0
Confirmed Partial Response6
Unconfirmed Partial Response1
Stable Disease2
Progressive Disease7
Not Evaluable1
SecondaryOverall Survival

Survival is defined as the time from the date of registration to the study to the date of death.

Time frame:
2 years post-registration
Reported as:
Number · Month

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events were collected from time of subject consent until 30 days after the completion of the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel, Gemcitabine and Bevacizumab—9/17 (52.9%)17/17 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventDocetaxel, Gemcitabine and Bevacizumab
Intestinal PerforationGastrointestinal disorders2/17
DysphagiaGastrointestinal disorders1/17
Gastrointestinal PerforationGastrointestinal disorders1/17
VomitingGastrointestinal disorders1/17
Deep Vein ThrombosisVascular disorders1/17
Hypertensive CrisisVascular disorders1/17
Jugular Vein ThrombosisVascular disorders1/17
Atrial FibrilationCardiac disorders1/17
Cardiac Failure CongestiveCardiac disorders1/17
Non-Small Cell Lung CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/17
Most frequent other events
Showing 10 of 103
Most frequent other events
EventDocetaxel, Gemcitabine and Bevacizumab
FatigueGeneral disorders9/17
Oedema PeripheralGeneral disorders8/17
CoughRespiratory, thoracic and mediastinal disorders8/17
AnaemiaBlood and lymphatic system disorders8/17
Mucosal inflammationGeneral disorders7/17
DiarrhoeaGastrointestinal disorders7/17
ConstipationGastrointestinal disorders6/17
NauseaGastrointestinal disorders6/17
AstheniaGeneral disorders4/17
StomatitisGastrointestinal disorders4/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Docetaxel, Gemcitabine and Bevacizumab
<=18 years0
Between 18 and 65 years10
>=65 years7
Age Continuous
Age Continuous(years)Docetaxel, Gemcitabine and Bevacizumab
Mean64.1 ± 11.74
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel, Gemcitabine and Bevacizumab
Female11
Male6
Region of Enrollment
Region of Enrollment(Participants)Docetaxel, Gemcitabine and Bevacizumab
USA17
Disease Stage at 1st diagnosis
Disease Stage at 1st diagnosis(Participants)Docetaxel, Gemcitabine and Bevacizumab
IA0
IB0
IIA0
IIB1
IIIA0
IIIB2
IV14
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Docetaxel, Gemcitabine and Bevacizumab
0 - Fully Active7
1 - Ambulatory, Restricted Activity8
2 - Ambulatory, No Work Activities2
3 - Limited Self Care, Partly Confined To Bed0
4 - Completely Disabled, No Self Care0
Histopathological Grade
Histopathological Grade(Participants)Docetaxel, Gemcitabine and Bevacizumab
G1 (well differentiated)1
G2 (moderately differentiated)3
G3 (poorly differentiated)3
G4 (undifferentiated)1
Unknown9
Tumor Histology
Tumor Histology(Participants)Docetaxel, Gemcitabine and Bevacizumab
Adenocarcinoma15
Bronchoalveolar Cell1
Large Cell1

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2006
First posted
Sep 20, 2006
Start
Jan 2007
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Jan 18, 2010
Last update
Jan 26, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00378573
Lead sponsor
Sanofi
First posted
Sep 20, 2006
Start date
Jan 2007
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Jan 18, 2010
Last update
Jan 26, 2010

Study contacts

Phyllis Diener, BS, MT (ASCP)
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Gemcitabine · Bevacizumab

Start the discussion